Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Armata Pharmaceuticals (ARMP) Research & Development (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed Research & Development for 6 consecutive years, with $2.0 million as the latest value for Q4 2018.

  • Quarterly Research & Development rose 82.02% to $2.0 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2018, up 106.17% year-over-year, with the annual reading at $23.7 million for FY2025, 31.11% down from the prior year.
  • Research & Development hit $2.0 million in Q4 2018 for Armata Pharmaceuticals, up from $1.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.6 million in Q4 2016 to a low of $41000.0 in Q3 2016.
  • Historically, Research & Development has averaged $1.6 million across 5 years, with a median of $1.2 million in 2016.
  • Biggest YoY gain for Research & Development was 356.87% in 2016; the steepest drop was 94.37% in 2016.
  • Year by year, Research & Development stood at $1.1 million in 2014, then rose by 9.16% to $1.2 million in 2015, then surged by 356.87% to $5.6 million in 2016, then crashed by 80.36% to $1.1 million in 2017, then soared by 82.02% to $2.0 million in 2018.
  • Business Quant data shows Research & Development for ARMP at $2.0 million in Q4 2018, $1.9 million in Q3 2018, and $2.3 million in Q2 2018.